期刊文献+

不同片段HIV-1膜蛋白三聚体的构建、表达及其免疫原性 被引量:1

Construction,expression and immunogenicity of HIV-1 envelope glycoprotein trimers at various lengths
原文传递
导出
摘要 目的构建、表达不同片段1型人类免疫缺陷病毒(human immunodeficiency virus type 1,HIV-1)的膜蛋白三聚体,并检测其免疫原性。方法以中国主要流行株HIV-1CRF_07 BC亚型基因为模板构建pFUSE-gp160重组质粒,以pFUSE-gp160为模板构建pFUSE-gp140FF、pFUSE-gp120FF、pFUSE-gp41FF、pFUSE-N55FF、pFUSE-N28FF重组质粒,将重组质粒分别转染293F细胞,转染120 h后,收获上清,经Ni-NTA superflow、nProtein A SepharoseTM4 Fast Flow及Superose 12 Prep Grade分子筛纯化后,分别进行SDS-PAGE及Western blot鉴定。将各重组蛋白联合MF59佐剂经大腿肌肉注射免疫豚鼠,100μg/只,分别于第1、30及60天各免疫1次,初次免疫前7 d及末次免疫后第90天心脏采血,分离血清,ELISA法及假病毒系统分别检测血清特异性抗体效价及中和抗体滴度。结果质粒pFUSE-gp160、pFUSE-gp140FF、pFUSE-gp120FF、pFUSE-gp41FF、pFUSE-N55FF、pFUSE-N28FF经测序鉴定构建正确。各纯化蛋白的SDS-PAGE及Western blot鉴定均可见目的条带,gp120FF和gp140FF均可高通量表达,其表达量分别为6和2.5 mg/L,gp41FF、N55FF和N28FF蛋白的表达量均低于0.5 mg/L,纯化后的纯度均较高。gp140FF组和gp120FF组豚鼠血清抗体效价分别为3.2×105和5.33×105、中和抗体滴度分别为405和462,均显著高于其他组(P<0.05)。结论 gp140FF和gp120FF能诱导豚鼠产生较强的体液免疫反应和中和抗体,本实验为HIV-1疫苗的研发提供了参考。 Objective To construct and express the recombinant envelope glycoprotein trimers of human immunodeficiency virus type 1(HIV-1),at various lengths,compare determine their immunogenicity. Methods Recombinant plasmid pFUSE- gp160 was constructed using the gene of prominent HIV-1 CRF_07 strain of subtypes BC in China as a template,based on which recombinant plasmids pFUSE-gp140FF,pFUSE-gp120FF,pFUSE-gp41FF,pFUSE-N55FF and pFUSE-N28FF were constructed and transfected to 293F cells respectively. The supernatant of transfected cells were collected 120 h lat- er,purified by Ni-NTA superflow,nProtein A SepharoseTM4 Fast Flow and Superose 12 Prep Grade molecular sieve chro- matography,and identified by SDS-PAGE and Western blot. Guinea pigs were injected i.m. with three doses of various recombinant proteins combined with MF59 adjuvant in legs,100 μg for each,on days 1,30 and 60 respectively. Heart blood samples were collected 7 d before the first injection and on day 90 after the last injection,from which sera were separated and determined for antibody potency and neutralizing antibody titer by ELISA and pseudovirus system. Results Sequencing proved that recombinant plasmids pFUSE-gp160, pFUSE-gp140FF, pFUSE-gp120FF, pFUSE-gp41FF, pFUSE-N55FF and pFUSE-N28FF were constructed correctly. The target bands of various purified proteins were observed on SDS-PAGE and Western blot profiles. The expression levels of gp120FF and gp140FF were 6 and 2. 5 mg / L respectively,while those of gp41FF, N55FF and N28FF were less than 0. 5 mg / L. The expressed products reached highpurities after purification. The serum antibody potencies of guinea pigs in gp140FF and gp120FF groups were 3. 2 × 105 and 5. 33 × 105,while the neutralizing antibody titers were 405 and 462, respectively, which were significantly higher than those in other groups(P〈 0. 05). Conclusion Both gp140FF and gp120FF induced strong humoral immune response and neutralizing antibody in guinea pigs, which provided a reference for development of HIV-1 vaccine.
出处 《中国生物制品学杂志》 CAS CSCD 2014年第2期145-150,共6页 Chinese Journal of Biologicals
基金 国家十二五科技重大专项-艾滋病和病毒性肝炎等重大传染病防治-DNA疫苗(2012ZX10001008-012) 传染病预防控制国家重点实验室留学归国人员项目资助(2012SKLID402)
关键词 1型人类免疫缺陷病毒 膜蛋白 三聚体 免疫原性 Human immunodeficiency virus type 1(HIV-1) Envelope glycoprotein Trimer Immunogenicity
  • 相关文献

参考文献12

  • 1Simon V,Ho DD,Abdool Karim Q. HIV / AIDS epidemiology,pathogenesis,prevention,and treatment[J].{H}LANCET,2006,(9534):489-504.
  • 2McCoy LE,Weiss RA. Neutralizing antibodies to HIV-1 induced by immunization[J].{H}Journal of Experimental Medicine,2013,(2):209-223.
  • 3Leaman DP,Zwick MB. Increased functional stability and homogeneity of viral envelope spikes through directed evolution[J].{H}PLoS Pathogens,2013,(2):e1003184.
  • 4胡新韬,洪坤学,赵春红,郝晓培,郑扬,任莉,阮玉华,邵一鸣.HIV-1B’亚型及CRF07_BC重组毒株感染者中和反应特征分析[J].中国热带医学,2011,11(4):391-394. 被引量:8
  • 5Burton DR,Desrosiers RC,Doms RW. HIV vaccine design and the neutralizing antibody problem[J].{H}Nature Immunology,2004,(3):233-236.
  • 6张聪优,万延民,许雪梅,徐建青.HIV-1包膜蛋白疫苗免疫原选择及改造策略研究进展[J].中华微生物学和免疫学杂志,2010,30(9):875-880. 被引量:5
  • 7Chen X,Lu L,Qi Z. Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides[J].{H}Journal of Biological Chemistry,2010,(33):25506-25515.
  • 8Qi Z,Pan CG,Lu H. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice[J].{H}Biochemical and Biophysical Research Communications,2010,(3):506-512.
  • 9张文艳,孔维,于湘晖.HIV-1 Vif蛋白的体内表达及其生物学功能[J].中国生物制品学杂志,2008,21(9):737-740. 被引量:2
  • 10Zhang MY,Wang Y,Mankowski MK. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc:possible role of the prolonged half-life of the immunogen[J].{H}VACCINE,2009,(6):857-863.

二级参考文献88

  • 1王淑华,邢辉,王建军,苏斌,陈曦,全宇,赵全璧,阮玉华,徐建青,宋艳辉,邵一鸣.安徽阜阳既往献血人群HIV-1感染者基因变异特征的研究[J].中华医学杂志,2007,87(22):1535-1539. 被引量:8
  • 2Flynn NM,Forthal DN,Harro CD,et al.Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.J Infect Dis,2005,191(5):654-665.
  • 3Pitisuttithum P,Gilbert P,Gurwith M,et al.Randomized,double-blind,placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok,Thailand.J Infect Dis,2006,194(12):1661-1671.
  • 4Russell ND,Graham BS,Keefer MC,et al.Phase 2 study of an HIV-1 canarypox vaccine(vCP1452)alone and in combination with rgpl20:negative results fail to trigger a phase 3 conrrelates trial.J Acquir Immune Defic Syndr,2007,44(2):203-212.
  • 5Rerks-Ngarm S,Pitisuttithum P,Nitayaphan S,et al.Vaccinmion with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.N Engl J Med,2009,361(23):2209-2220.
  • 6Quinnan GV Jr,Zhang PF,Fu DW,et al.Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response.AIDS Res Hum Retroviruses,1999,15(6):561-570.
  • 7Zhang PF,Cham F,Dong M,et al.Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization.Proc Natl Acad Sci USA,2007,104(24):10193-10198.
  • 8Zhang PF,Bouma P,Park EJ,et al.A variable region 3(V3)mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive,primary virusneutralizing antibody response.J Virol,2002,76(2):644-655.
  • 9Choudhry V,Zhang MY,Sidorov IA,et al.Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140)isolated from a patient(R2)with broadly HIV-1 neutralizing antibodies.Virology,2007,363(1):79-90.
  • 10McBurney SP,Ross TM.Viral sequence diversity:challenges for AIDS vaccine designs.Expert Rev Vaccines,2008,7(9):1405-1417.

共引文献12

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部